Equities analysts expect Jounce Therapeutics Inc (NASDAQ:JNCE) to report ($0.59) earnings per share for the current quarter, according to Zacks. Two analysts have provided estimates for Jounce Therapeutics’ earnings. The highest EPS estimate is ($0.22) and the lowest is ($1.04). Jounce Therapeutics posted earnings of $0.05 per share during the same quarter last year, which suggests a negative year over year growth rate of 1,280%. The company is scheduled to report its next earnings report on Friday, March 9th.
On average, analysts expect that Jounce Therapeutics will report full year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($1.29) to ($0.49). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.58) to ($1.15). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.12. The company had revenue of $18.10 million during the quarter, compared to analyst estimates of $20.00 million. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The firm’s revenue was up 7.1% compared to the same quarter last year.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Teachers Advisors LLC grew its position in shares of Jounce Therapeutics by 26.4% in the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after purchasing an additional 2,347 shares during the period. Strs Ohio grew its position in shares of Jounce Therapeutics by 10.7% in the 3rd quarter. Strs Ohio now owns 41,300 shares of the company’s stock valued at $643,000 after purchasing an additional 4,000 shares during the period. American International Group Inc. grew its position in shares of Jounce Therapeutics by 132.2% in the 3rd quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after purchasing an additional 5,442 shares during the period. OxFORD Asset Management LLP grew its position in shares of Jounce Therapeutics by 11.9% in the 3rd quarter. OxFORD Asset Management LLP now owns 59,540 shares of the company’s stock valued at $927,000 after purchasing an additional 6,328 shares during the period. Finally, Macquarie Group Ltd. acquired a new position in shares of Jounce Therapeutics in the 3rd quarter valued at approximately $124,000. Institutional investors and hedge funds own 47.51% of the company’s stock.
Jounce Therapeutics (NASDAQ:JNCE) traded up $1.00 during trading on Friday, hitting $16.37. The stock had a trading volume of 187,299 shares, compared to its average volume of 149,735. The firm has a market cap of $495.62 and a price-to-earnings ratio of -77.95. Jounce Therapeutics has a 52 week low of $11.05 and a 52 week high of $29.29.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.